Codelivery of salinomycin and doxorubicin using nanoliposomes for targeting both liver cancer cells and cancer stem cells. (October 2016)

• Record Type: Journal Article
• Authors: Gong, Zhirong; Chen, Dazhong; Xie, Fangyuan; Liu, Junjie; Zhang, He; Zou, Hao; Yu, Yuan; Chen, Yan; Sun, Zhiguo; Wang, Xinxia; Zhang, Hai; Zhang, Guoqing; Yin, Chuan; Gao, Jie; Zhong, Yanqiang; Lu, Ying
• Is Part Of: Nanomedicine. Volume 11:Number 19(2016)
• Page Start: 2565
• Page End: 2579
• Publication Date: 2016-10
• Subjects: cancer stem cells -- combined therapy -- doxorubicin -- liver cancer -- nanoliposomes -- salinomycin; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm-2016-0137
• Languages: English
• ISSNs: 1743-5889

Abstract

Aim: To develop salinomycin-loaded nanoliposomes (SLN), doxorubicin-loaded nanoliposomes (DLN) and nanoliposomes codelivering salinomycin and doxorubicin (SDLN) to target both liver cancer cells and cancer stem cells.Materials & methods: The characterization and antitumor activity of SLN, DLN and SDLN were evaluated.Results & conclusion: The doxorubicin/salinomycin sodium mole ratio of 1:1 had the best synergistic combination index value, and was chosen as the drug ratio in SDLN. SDLN could maintain the drug ratio between 1:1 and 3:1 in 12 h in vivo . SDLN and SLN + DLN showed the best tumor inhibitory rate, and could significantly decrease the percentage of liver cancer stem cells in vivo . SDLN and SLN + DLN may serve as an effective approach to treat liver cancer.